LENZ Therapeutics
LENZ
144 hedge funds and large institutions have $197M invested in LENZ Therapeutics in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 34 reducing their positions, and 27 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 34
5.04% more ownership
Funds ownership: 105.69% → 110.73% (+5%)
4% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 27
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 145 → 144 (-1)
28% less call options, than puts
Call options by funds: $874K | Put options by funds: $1.22M
35% less capital invested
Capital invested by funds: $303M → $197M (-$106M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.15M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.89M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$3.16M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.93M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$10.1M |
| 2 |
SAM
Silvercrest Asset Management
New York
|
-$2.59M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.35M |
| 4 |
Two Sigma Investments
New York
|
-$1.74M |
| 5 |
Morgan Stanley
New York
|
-$1.42M |
LENZ Hedge Fund Activity: Q2 2026 in Review
144 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2026, worth a combined $197M — down 35% from $303M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new LENZ positions and 27 closed out — a net gain of 1 holder — while 59 added to existing stakes and 34 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.15M. The largest seller was Franklin Resources, exiting entirely with an estimated $10.1M sold.
- 144 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2026, down from 145 in Q1 2026.
- Funds reported $197M of LENZ Therapeutics stock for Q2 2026, down 35% quarter-over-quarter.
- 28 funds opened new LENZ Therapeutics positions in Q2 2026 and 27 closed out, a net change of +1 holder.
- The largest LENZ Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $5.15M added.
- The largest LENZ Therapeutics seller in Q2 2026 was Franklin Resources, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2026.